“We think this is a stock picker’s market,” Shulman said, going on to explain that genomic stocks such as Intellia Therapeutics (CRSP) go up with scientific breakthroughs. Of particular concern to Shulman is the cost-push of food prices and the effects that will be felt from the drought in the western part of the country. Intellia’s recent breakthrough in using CRISPR technology to successfully give treatment via IV saw the stock climb 110%.